Scientists Announce First Successful Gene Therapy for Sickle Cell Disease
An international team of researchers has announced the success of the first gene therapy for sickle cell disease and beta-thalassemia using the CRISPR-Cas9 gene-editing technology. This breakthrough comes just months after receiving approval from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
The therapy, named “Casgevy,” works by modifying the patient’s DNA in a laboratory to activate fetal hemoglobin production, which compensates for the genetic mutations responsible for these diseases. Clinical trials showed that 97% of sickle cell patients who received the treatment experienced no severe pain episodes for at least a year, while 93% of beta-thalassemia patients no longer required regular blood transfusions.
Experts highlight that this new technique reprograms the patient’s stem cells without affecting other genes, reducing potential side effects.
